Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 5 of 30
Song-making In a Group (SING)
NCT05929352
Alcohol-ROC-Training
NCT05491551
Promoting Alcohol Treatment Engagement Post-hospitalization
NCT05338151
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
NCT05176418
Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study
NCT05279092
Intestinal Immunity in Neurologic Disease
NCT06329453
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
NCT05260047
SV2A in Older Adults
NCT05465538
Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)
NCT05377840
Cardiovascular Disease Risk in Women With Endometriosis
NCT03746535
Identifying and Characterizing Preclinical MS
NCT05787795
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
NCT05323487
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
NCT05203965
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
NCT04924322
SV2A Density Cannabis Use Disorder
NCT05472818
Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)
NCT04936009
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT05002816
Pharmacological and Behavioral Treatment After Bariatric Surgery
NCT05157698
Cannabidiol in Opioid Use Disorder and Chronic Pain
NCT04587791
CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions
NCT05145478
The Stimulation To Induce Mothers Study
NCT05079841
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
NCT04738825
Genomic Predictors of Recurrent Pregnancy Loss
NCT05444283
Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study
NCT04721418
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
NCT04366518
Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care
NCT04661072
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
NCT04793685
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
NCT04599478
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT04634643
CBD-Microglia PET Study
NCT04398719
Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke
NCT04760717
Ertugliflozin in Chronic Heart Failure
NCT04438213
Stress and Congestive Heart Failure
NCT04551560
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
NCT04210492
Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders
NCT03764098
Rheumatology Patient Registry and Biorepository
NCT04402086
Operative Versus Non-Operative Management for Appendicitis With Abscess or Phlegmon
NCT04168866
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
NCT04131829
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
NCT04704271
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
NCT04237701
The Recovery in Stroke Using PAP Study
NCT04130503
Effects of Dronabinol in Opioid Maintained Patients
NCT04025359
The Impact of Phosphate Metabolism on Healthy Aging
NCT03771105
Natural History of Wilson Disease
NCT03334292
SV2 PET Imaging With [11C]APP311
NCT03995121
Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia
NCT03592290
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
NCT02811510
Imaging SV2A in Mood Disorders
NCT02734602
The EXPLORE MG Registry for Myasthenia Gravis
NCT03792659
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.